Navigation Links
Abbott's Investigational MitraClip(R) System Demonstrates Strong Safety Results and Improved Clinical Outcomes for Common Causes of Leaky Heart Valves
Date:5/25/2010

The patient subgroup analysis included 135 patients with DMR and 49 patients with FMR. At one year, the MitraClip procedure demonstrated the following results in FMR and DMR patients:

  • An improvement in heart function as indicated by a reduction in both left ventricular end diastolic volume (LVEDV) and left ventricular end systolic volume (LVESV). In FMR patients, LVEDV decreased 10.6 percent and LVESV decreased 7.7 percent compared to baseline. Similarly, in DMR patients, LVEDV decreased 15 percent and LVESV decreased 6.7 percent compared to baseline.
  • An improvement in symptoms, with 96.7 percent of FMR patients and 97.8 percent of DMR patients exhibiting no symptoms (NYHA Functional Class I) or mild symptoms (NYHA Functional Class II), whereas at baseline, 64.5 percent of FMR patients and 45.2 percent of DMR patients had moderate symptoms (NYHA Functional Class III) or severe symptoms (NYHA Functional Class IV). Patients who are classified as NYHA Functional Class III or IV experience marked or severe limitations in physical activity.
  • Meaningful improvements in both physical and mental quality of life compared to baseline as measured by the SF-36 Survey (increase of 1.6 points for FMR patients and 5.6 points for DMR patients in the physical quality of life score, and increase of 8.7 points for FMR patients and 5.0 points for DMR patients in the mental quality of life score).

About Mitral Regurgitation

MR is the most common type of heart valve insufficiency in the United States and Europe, affecting millions of people worldwide. MR affects more than 8 million people in the United States and Europe. There are more than 600,000 new diagnoses of s
'/>"/>

SOURCE Abbott
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
2. A Worldwide Phase III Clinical Trial Seeks U.S. Patients to Explore Investigational Drug Phenoxodiol
3. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
4. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
5. Replidynes Investigational Antibacterial Agent REP3123 Prevents Sporulation in Clostridium difficile
6. Replidynes Investigational Antibacterial Agent REP3123 Prevents Toxin Production in Clostridium difficile
7. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
8. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
9. KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
10. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
11. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... MEETING, Pa. , Sept. 22, 2014 /PRNewswire/ ... announced today it has initiated a phase I ... trial will evaluate the safety, tolerability, and immunogenicity ... 6 (HPV-6), which causes most aerodigestive cancers. ... nose, throat, vocal cords, and parts of the ...
(Date:9/22/2014)... SAN DIEGO , Sept. 22, 2014 Arena ... the company is scheduled to present a corporate overview ... conference on Friday, September 26, 2014, at 11:30 a.m. ... Broadway Hotel in New York City ... presentation will be available under the investor relations section ...
(Date:9/22/2014)... Sept. 22, 2014 Thoratec Corporation (NASDAQ: ... circulatory support therapies to save, support and restore failing ... has been appointed President and Chief Executive Officer, effective ... has stepped down from his executive and Board roles ... through the first quarter of 2016.  ...
Breaking Medicine Technology:Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 2Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 3Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 4Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference 2Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference 3Thoratec Appoints D. Keith Grossman President And Chief Executive Officer 2Thoratec Appoints D. Keith Grossman President And Chief Executive Officer 3Thoratec Appoints D. Keith Grossman President And Chief Executive Officer 4Thoratec Appoints D. Keith Grossman President And Chief Executive Officer 5
(Date:9/22/2014)... Angeles, CA (PRWEB) September 22, 2014 ... life insurance industry is now easier using the Quotes ... who are trying to local universal life insurance pricing ... The adult coverage plans that are easily viewed when ... that underwrite specific lengths of coverage. The plan data ...
(Date:9/22/2014)... Manhattan residents who suffer with hip ... hip , which could be bursitis now have a ... now offered at New York Dynamic Neuromuscular Rehabilitation Center. ... occurs when the trochanteric bursa becomes irritated or inflamed. ... between the iliotibial band and the greater trochanter. Most ...
(Date:9/22/2014)... seems futuristic, if not impossible. But with a ... researchers at University of California, San Diego School ... an entire, functional eye a reality. , "A ... for vision restoration," said Jeffrey Goldberg, MD, PhD, ... at University of Pittsburg Medical Center and Boston ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 This Flash ... on stakeholder management needs for the Prostate Cancer market. ... Experts on stakeholder strategies for any launching Prostate Cancer ... of differentiation within an increasingly crowded market , ... The impact of identifying community-based thought leaders and stakeholders ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 The ... the nation’s leading nonprofit authority on the use ... information exchange, announced findings from its recent industry ... Plan Identifier (HPID) within electronic transactions adopted under ... WEDI conducted the survey from August 20 to ...
Breaking Medicine News(10 mins):Health News:Universal Life Insurance Prices for Adults Added to National Insurer Portal Online 2Health News:DNR Clinic Offers Hip Bursitis Treatment in Manhattan 2Health News:DNR Clinic Offers Hip Bursitis Treatment in Manhattan 3Health News:Looking ahead: Whole eye transplant under development 2Health News:Download HeartBeat Experts White Paper: Stakeholder Management for new Prostate Cancer Products 2Health News:WEDI Announces Survey Results from Unique Health Plan Identifier (HPID) Industry Poll 2Health News:WEDI Announces Survey Results from Unique Health Plan Identifier (HPID) Industry Poll 3
... aiding joint inflammations in conditions like // arthritis. ... of the immune cells to secrete chemicals that will ... to arthritis. The enzyme cathepsin G attracts accumulation of ... tissue and cartilage in joints leading to the inflammatory ...
... a common water pollutant called arsenic may not be the ... a gene called CYT19 in people, particularly in children, that ... arsenic. ,Arsenic exposure had long been associated with health ... problems, and neurological disorders. It can enter the body through ...
... could run using a pollution free energy source.// ... working towards this solution to look at making hydrogen fuel ... hydrogen would reacts with oxygen to produce water and energy. ... would be pollution free. A similar mechanism is already followed ...
... had lead to inability to curbing of inflammatory cells// ... likewise. Researchers from Oregon Health & Science University have ... the low immune problem that leads to progress of ... disease of the central nervous system. There is no ...
... Prostate cancer is the commonest cancer effecting men. Benefits ... watermelon, papaya and pink grapefruit( most lycopene in processed ... known for sometime in preventing the aging process ... It is now being looked at for preventing and ...
... People suffering from diabetes type 1 or type 2 ... tract infections and skin infections. ,Some other ... kidney damage, nerve damage, eye problems that can lead ... a major risk factor for incidence of diabetes of ...
Cached Medicine News:Health News:Pollution Free Hydrogen based fuel for Energy 2Health News:Pollution Free Hydrogen based fuel for Energy 3
Designed to meet the requirements of reagent grade water for routine analysis....
... L/min of Type I ultrapure water, , ... Plus System is designed to provide the ... pretreated by reverse osmosis, distillation or deionization. ... quality which exceeds Type I ASTM/CAP/NCCLS specifications.,The ...
... Basic Laboratory Needs, Synergy systems produce ultrapure water ... 1 to 1.2 L/min to meet the basic ... incorporates a dual-wavelength UV lamp (185 nm and ... of organic contaminants (< 5 ppb TOC when ...
... Compact System Produces Type I Water Directly from ... designed for scientists who need 5 to 15 ... not have easy access to acceptable quality pretreated ... 0.6 L/min of ultrapure (Type I) water on ...
Medicine Products: